Amphastar Pharmaceuticals, Inc.
General ticker "AMPH" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $1.1B (TTM average)
Amphastar Pharmaceuticals, Inc. does not follow the US Stock Market performance with the rate: -11.8%.
Estimated limits based on current volatility of 2.8%: low 25.32$, high 26.78$
Factors to consider:
- Total employees count: 1976 (-2.6%) as of 2025
- US accounted for 96.7% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Dependence on key products, Supply chain disruptions, Regulatory and compliance, Market competition, Labor/talent shortage/retention
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [21.99$, 33.26$]
- 2026-12-31 to 2027-12-31 estimated range: [23.37$, 35.04$]
Financial Metrics affecting the AMPH estimates:
- Positive: with PPE of 8.3 at the end of fiscal year the price was neutral
- Positive: 15.80 < Operating profit margin, % of 19.50
- Positive: 11.37 < Operating cash flow per share per price, % of 12.42
- Positive: Industry inventory ratio change (median), % of -0.31 <= 0
- Negative: negative Industry operating cash flow (median)
- Positive: 5.14 < Return on assets ratio (scaled to [-100,100]) of 5.68
- Negative: Industry earnings per price (median), % of 0 <= 0
- Negative: Investing cash flow per share per price, % of -5.59 <= -4.49
- Negative: 1.42 < Interest expense per share per price, % of 2.03
- Positive: Inventory ratio change, % of 2.37 <= 4.02
- Negative: 42.26 < Shareholder equity ratio, % of 48.41 <= 49.86
Short-term AMPH quotes
Long-term AMPH plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $644.39MM | $731.97MM | $719.89MM |
| Operating Expenses | $447.41MM | $526.55MM | $579.48MM |
| Operating Income | $196.99MM | $205.42MM | $140.40MM |
| Non-Operating Income | $-25.63MM | $-15.65MM | $-16.78MM |
| Interest Expense | $27.16MM | $30.34MM | $25.48MM |
| R&D Expense | $73.74MM | $73.91MM | $85.84MM |
| Income(Loss) | $171.36MM | $189.76MM | $123.62MM |
| Taxes | $31.83MM | $29.67MM | $25.53MM |
| Other Income(Loss) | $-1.98MM | $-0.57MM | $0.00MM |
| Net Income(Loss)* | $137.54MM | $159.52MM | $98.09MM |
| Stockholders Equity | $639.42MM | $732.30MM | $788.80MM |
| Inventory | $105.83MM | $153.74MM | $176.89MM |
| Assets | $1,512.91MM | $1,577.47MM | $1,629.30MM |
| Operating Cash Flow | $183.50MM | $213.39MM | $156.12MM |
| Capital expenditure | $38.17MM | $41.04MM | $34.88MM |
| Investing Cash Flow | $-649.12MM | $-124.93MM | $-70.33MM |
| Financing Cash Flow | $454.09MM | $-80.95MM | $-67.42MM |
| Earnings Per Share** | $2.85 | $3.29 | $2.10 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.